Comparative Pharmacology
Head-to-head clinical analysis: NORQUEST FE versus PORTIA 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORQUEST FE versus PORTIA 28.
NORQUEST FE vs PORTIA-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NORQUEST FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Norethindrone induces progestational changes in the endometrium, increasing cervical mucus viscosity, and also inhibits ovulation.
Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin release, inhibiting ovulation; progestin (levonorgestrel) alters cervical mucus and endometrial lining.
One tablet orally once daily, each tablet containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol (21 active tablets) followed by 7 ferrous fumarate tablets.
One tablet (levonorgestrel 0.15 mg, ethinyl estradiol 0.03 mg) orally once daily
None Documented
None Documented
Terminal half-life: 6-8 hours. Clinical context: Supports once-daily dosing with sustained therapeutic effect.
Levonorgestrel: 24-30 hours; ethinyl estradiol: 12-15 hours. Clinical context: Steady-state achieved within 5-7 days.
Renal: 80% (50% unchanged, 30% as metabolites); Fecal: 19%; Biliary: <1%
Renal (60-70% as metabolites, 20-30% as levonorgestrel/ethinyl estradiol glucuronides), fecal (10-20%), biliary (minor).
Category C
Category C
Oral Contraceptive
Oral Contraceptive